rs11920090

This is a regulatory region variant variant in the SLC2A2 gene.

▶

GWAS Catalog Trait Associations (3)

Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.

blood glucose amount

Lagou V et al. “Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability.” Nature Communications 12(1):24 (2021)
Allele T
OR 0.03
p 3.0e-8
N 67,506
Large GWAS
European
Wessel J et al. “Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility.” Nature Communications 6:5897 (2015)
Allele T
OR 0.02
p 5.0e-8
N 60,564
Large GWAS
multi-ancestry
Manning AK et al. “A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance.” Nature Genetics 44(6):659-69 (2012)
Allele T
OR 0.03
p 2.0e-9
N 58,074
Large GWAS
European
Dupuis J et al. “New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk.” Nature Genetics 42(2):105-116 (2010)
Allele T
OR 0.02
p 8.0e-13
N 46,186
Large GWAS
European
▶

Research that mentions this SNP (2)

▶
Sugar-sweetened beverage intake associations with fasting glucose and insulin concentrations are not modified by selected genetic variants in a ChREBP-FGF21 pathway: a meta-analysis
Meta-analysisN=34,748McKeown NM et al.(2018)· Diabetologia

Meta-analysis of 34,748 European ancestry adults from 11 CHARGE Consortium cohorts examining sugar-sweetened beverage (SSB) intake associations with glycemic traits. SSB intake was associated with higher fasting glucose (β=0.014 mmol/l, p=1.5×10⁻³) and fasting insulin (β=0.030 log pmol/l, p=2.0×10⁻¹⁰). Although a suggestive interaction between SSB and KLB-rs1542423 was observed in discovery cohorts for fasting insulin (p=0.006), this was not confirmed in replication analysis.

Traits studied:Fasting glucoseFasting insulinGlycemic traitsType 2 diabetes
PubMedDOIMetascience Observatory
▶
PROX1 Gene Variant is Associated with Fasting Glucose Change After Antihypertensive Treatment
AssociationN=456Yan Gong et al.(2014)· Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

A pharmacogenomics study of 456 hypertensive participants examining whether fasting glucose GWAS variants predict glucose response to antihypertensive medications. The primary finding was that PROX1 rs340874 (C allele) was significantly associated with greater glucose elevation after 9 weeks of atenolol monotherapy (p=0.0013, beta = +2.39 mg/dL per allele). Two additional SNPs showed nominal associations: ARAP1 rs11603334 with atenolol response and SLC2A2 rs11920090 with HCTZ response.

Traits studied:Atenolol-induced hyperglycemiaFasting glucoseGlucose response to antihypertensive drugsHydrochlorothiazide-induced hyperglycemiaHypertension
PubMedDOIMetascience Observatory

About SLC2A2

This gene encodes an integral plasma membrane glycoprotein of the liver, islet beta cells, intestine, and kidney epithelium. The encoded protein mediates facilitated bidirectional glucose transport. Because of its low affinity for glucose, it has been suggested as a glucose sensor. Mutations in this gene are associated with susceptibility to diseases, including Fanconi-Bickel syndrome and noninsulin-dependent diabetes mellitus (NIDDM). Alternative splicing results in multiple transcript variants of this gene. [provided by RefSeq, Jul 2013]

View all SLC2A2 variants →

Gene information from NCBI Gene. Variant classifications from ClinVar.

Community Wiki

No community notes yet for this variant. Sign in to start one.

Comments

Sign in to join the discussion.

Loading comments…